Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCQ + Abemaciclib in Advanced Solid Tumors and Breast Cancer
NCT04316169Phase 1Withdrawn
- Sponsor
- Medical College of Wisconsin
- Start
- Oct 2021
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hydroxychloroquine in solid tumor and breast cancer (4 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Dose-limiting toxicities at 28 days. Planned start Oct 2021; status: withdrawn.
02
Drugs
hydroxychloroquine
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT04316169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316169.